These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 8185351)
21. [Adjuvant chemotherapy for non-small cell lung cancer]. Otake Y; Tanaka F; Wada H; Hitomi S Gan To Kagaku Ryoho; 1997 Aug; 24(10):1245-51. PubMed ID: 9279343 [TBL] [Abstract][Full Text] [Related]
22. [Outpatient chemotherapy for small cell lung cancer in our hospital]. Minami S; Asai M; Iwahori K; Kouga K; Nishiyama A; Komuta K Gan To Kagaku Ryoho; 2002 Sep; 29(9):1661-4. PubMed ID: 12355957 [No Abstract] [Full Text] [Related]
23. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Kaira K; Sunaga N; Yanagitani N; Imai H; Utsugi M; Shimizu Y; Iijima H; Tomizawa Y; Hisada T; Ishizuka T; Saito R; Mori M Anticancer Drugs; 2007 Apr; 18(4):471-6. PubMed ID: 17351400 [TBL] [Abstract][Full Text] [Related]
24. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Neill HB; Miller AA; Clamon GH; Perry MC; Crawford J; Green MR Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-130-S12-134. PubMed ID: 9331137 [TBL] [Abstract][Full Text] [Related]
25. [Carboplatin-Vepeside in the treatment of non-small cell bronchial cancers. A phase II study]. Heckmayr M; Gatzemeier U; Hossfeld DK; Achterrath W Pneumologie; 1990 Feb; 44 Suppl 1():588-9. PubMed ID: 2164205 [TBL] [Abstract][Full Text] [Related]
26. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Ghielmini M; Pagani O; de Jong J; Pampallona S; Conti A; Maestroni G; Sessa C; Cavalli F Br J Cancer; 1999 Jun; 80(7):1058-61. PubMed ID: 10362116 [TBL] [Abstract][Full Text] [Related]
27. [Outpatient chemotherapy with oral UFT (tegafur and uracil) and cisplatin against metastatic non-small cell lung carcinoma--an effective case]. Uehara T; Yano T; Kanematsu T; Terazaki Y; Kuninaka S; Fukuyama Y; Yokoyama H; Asoh H; Ichinose Y Gan To Kagaku Ryoho; 1999 Jan; 26(1):137-9. PubMed ID: 9987510 [TBL] [Abstract][Full Text] [Related]
28. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer]. Li DX; Chen XB Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023 [TBL] [Abstract][Full Text] [Related]
29. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer. Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138 [TBL] [Abstract][Full Text] [Related]
31. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Tanaka F; Otake Y; Yanagihara K; Yamada T; Miyahara R; Kawano Y; Li M; Inui K; Wada H Br J Cancer; 2001 Jan; 84(2):263-9. PubMed ID: 11161386 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995. Lee YC; McCrystal MR; Christmas TI N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564 [TBL] [Abstract][Full Text] [Related]
33. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer. Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820 [TBL] [Abstract][Full Text] [Related]
34. [Disease-free survival in a patient with squamous cell lung carcinoma following complete response with the combination chemotherapy of cisplatin and etoposide]. Taniwaki M; Kakusui M; Imoto M; Takashima T; Misawa S; Kashima K Gan To Kagaku Ryoho; 1993 May; 20(7):949-52. PubMed ID: 8489301 [TBL] [Abstract][Full Text] [Related]
35. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM; Pazdur R; Benner SE; Canetta R Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235 [TBL] [Abstract][Full Text] [Related]
36. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
37. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931 [TBL] [Abstract][Full Text] [Related]
38. Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change? Diasio RB N Engl J Med; 2004 Apr; 350(17):1777-9. PubMed ID: 15103005 [No Abstract] [Full Text] [Related]
39. [Chemotherapy with high dose CBDCA for advanced non-small cell lung cancer]. Daido K; Arita K; Ejima T Gan To Kagaku Ryoho; 1992 Jan; 19(1):123-5. PubMed ID: 1309631 [No Abstract] [Full Text] [Related]
40. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Feliu J; González Barón M; Zamora P; Garcia Alfonso P; Garcia Girón C; Blanco E; Belón J; Garrido P; Jara C; Ruiz A; Vincent JM; Espinosa E Oncology; 1997; 54 Suppl 1():30-7. PubMed ID: 8978582 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]